Abstract
The targeting of tumors is made possible through establishing protein signatures
specific for each cancer type. The recent recognition of the higher expression levels
of HSP90 and its accumulation in tumor cell mitochondria has made the HSP90 network a
feasible target for neutralization. HSP90 antagonizes the mitochondrial permeability
transition, blocking cytochrome c release and apoptosis. In this
issue of the JCI, Kang et al. report the synthesis of Gamitrinibs,
which target mitochondrially localized HSP90, specifically killing human cancer cell
lines, and provide a fresh approach for cancer treatment (see the related article
beginning on page 454).
Authors
Çiǧdem Atay, Serkan Uǧurlu, Nesrin Özören
×
Download this citation for these citation managers:
Or, download this citation in these formats:
If you experience problems using these citation formats, send us feedback.